Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICARIA: Azithromycin Plus IPTi Through EPI in Sierra Leone
NCT04235816Phase 3Active, not recruiting
- Sponsor
- Barcelona Institute for Global Health
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in child mortality (U5MR) comparing Group 1: Azithromycin with Group 2: Placebo (2 arms). Primary endpoint: Rate of all-cause mortality at 18 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
azithromycin
03
Conditions
child mortality (U5MR)
Beyond the preview
Go deeper on NCT04235816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235816.